The proposal is to add words in red text and to delete words or statements with a strikethrough:
|
|
- Samuel Arnold
- 5 years ago
- Views:
Transcription
1 Plicy Medical Plicy Manual Draft Revised Plicy: D Nt Implement Plasma Exchange DESCRIPTION Plasma exchange (PE) is a prcedure in which the bld f the patient is extracted and prcessed thrugh a medical device which separates the plasma frm ther cmpnents f bld. The plasma is discarded and replaced with fluid such as albumin, allgenic plasma r a plasma substitute. PE is a nnspecific therapy, because the entire plasma is discarded. PE has been used in a wide variety f acute and chrnic cnditins, as well as in the setting f slid rgan transplantatin. The terms therapeutic apheresis, plasmapheresis, and plasma exchange are ften used interchangeably, but when prperly used dente different prcedures. The American Sciety fr Apheresis (ASFA) definitins fr these ther prcedures are as fllws: Apheresis: A prcedure in which whle bld f the patient r dnr is passed thrugh a medical device which separates ut any f the particular cmpnents f the bld and returns the remainder t circulatin, with r withut extracrpreal treatment r replacement f the separated cmpnent. Plasmapheresis: A prcedure in which whle bld is passed thrugh a medical device that separates the plasma frm the ther cmpnents f the bld. The red and white bld cells are transfused back int the persn, the plasma is discarded withut a replacement slutin. The prpsed therapeutic use f PE is t rapidly remve txins r autantibdies which can accumulate in the plasma as a result f a disease prcess. PE is a nn-specific therapy and essentially a symptmatic treatment since it des nt remve the surce f the pathgenic factrs. Althugh PE can rapidly reduce levels f serum autantibdies; a feedback mechanism may lead t a rebund verprductin f the same antibdies. Nte: Applicatins f PE can be bradly subdivided int 2 general categries: (1) acute self-limited diseases, in which PE is used t lwer the circulating pathgenic substance; and (2) chrnic diseases, in which there is nging prductin f pathgenic autantibdies. Treatment gals and duratin f treatment with PE need t be clearly established befre its initiatin; withut such treatment gals, the use f an acute shrt-term curse f PE may insidiusly evlve t a chrnic use f PE with uncertain benefit. Fr example a meaningful clinical respnse fr chrnic inflammatry demyelinating plyneurpathy (CIDP) wuld be an imprvement in neurlgical disability scres (e.g. Hughes GBS Disability Scale, Overall Disability Sum Scre). Hwever, studies shw prgress made will mst likely last nly fr the shrt term. Anther example wuld be plasma exchange when used t treat myasthenia gravis r Guillain-Barre wuld shw measurable imprvement in bedside spirmetry readings. Additinally neurmyelitis ptica and neurmyelitis ptica spectrum disrder (NMO/NMOSD), a rare but clinically aggressive demyelinating disease f the central nervus system, that des nt respnd t initial treatment f sterids may respnd t a shrt curse f plasma exchange treatments, especially if previus treatments resulted in imprvements in visual acuity r disability scres. POLICY The prpsal is t add wrds in red text and t delete wrds r statements with a strikethrugh: Plasma exchange is cnsidered medically necessary fr specified diseases/cnditins if the medical apprpriateness criteria are met. (See Medical Apprpriateness belw.) Plasma exchange fr the treatment f all ther diseases/cnditins including, but nt limited t the fllwing is cnsidered investigatinal: This dcument has been classified as public infrmatin
2 Plicy Medical Plicy Manual Draft Revised Plicy: D Nt Implement ABO incmpatible slid rgan transplant; liver Acute disseminated encephalpathy Acute inflammatry demyelinating plyneurpathy (Guillain-Barré syndrme) in children yunger than 10 with mild r mderate frms Acute liver failure Amytrphic lateral sclersis Aplastic anemia Asthma Autimmune hemlytic anemia; warm hemlytic anemia; cld agglutinin disease Bullus pemphigid Cardimypathy, pst-transplant Central pntine myelinlysis Chrnic fatigue syndrme Cagulatin factr inhibitrs Cryglbulinemia; (except fr severe mixed cryglbulinemia, as nted belw) Heart transplant antibdy mediated rejectin Hemlytic uremic syndrme (HUS) with typical presentatin (diarrhea related) Idipathic thrmbcytpenic purpura (ITP); refractry r nn-refractry Inclusin bdy mysitis Lambert-Eatn myasthenic syndrme Mild Guillain-Barré syndrme Multiple sclersis; chrnic prgressive r relapsing remitting Mushrm pisning Myasthenia gravis with anti-musk antibdies Obsessive-cmpulsive disrder and tic disrder f childhd Overdse and pisning (ther than mushrm) Paraneplastic syndrmes Paraprteinemic plyneurpathy, (IgM) Pediatric autimmune neurpsychiatric disrders assciated with streptcccal infectins (PANDAS) Pemphigus vulgaris Phytanic acid strage disease (Refsum s disease) POEMS (plyneurpathy, rganmegaly, endcrinpathy, M prtein, skin changes) Plymysitis and dermatmysitis Psriasis Raynaud's phenmenn Red cell allimmunizatin in pregnancy Reginal enteritis (Crhn's disease) Rheumatid arthritis Sclerderma (systemic sclersis) Severe late left ventricular failure Stiff persn syndrme Sydenham s chrea (SC) Systemic lupus erythematsus; manifestatins ther than nephritis Systemic Lupus nephritis Systemic vasculitis t imprve renal functin Thyrtxicsis MEDICAL APPROPRIATENESS Plasma exchange is cnsidered medically apprpriate if ANY ONE f the fllwing are met: Autimmune This dcument has been classified as public infrmatin
3 Plicy Medical Plicy Manual Draft Revised Plicy: D Nt Implement Severe multiple manifestatin f mixed cryglbulinemia (e.g. cryglbulinemic nephrpathy, skin ulcers, sensry mtr neurpathy and widespread vasculitis) used in cnjunctin with immunsuppressive treatment Catastrphic anti-phsphlipid syndrme (CAPS) Pediatric pst-infectius autimmune neurpsychiatric disrders (e.g., PANDAS, Sydenham s Chrea; which typically fllw Grup-A beta-hemlytic streptcccus infectin) Wilsn s Disease, fulminant (autsmal recessive genetic disrder resulting in cpper accumulatin in the liver, brain, crnea, and kidney) Hematlgic ABO incmpatible hematpietic prgenitr cell transplantatin Hyperviscsity syndrme and ANY ONE f the fllwing: multiple myelma Waldenström's macrglbulinemia Thrmbtic thrmbcytpenia purpura (TTP) Idipathic thrmbcytpenia purpura (ITP) in emergency situatin Atypical hemlytic-uremic syndrme (HUS) Pst transfusin purpura HELLP syndrme f pregnancy (a severe frm f preeclampsia, characterized by hemlysis [H], elevated liver enzymes [EL], and lw platelet [LP] cunts) Myelma with acute renal failure IgA r IgG paraprteinemia plyneurpathy Transplant Slid rgan transplantatin with ABO incmpatibility r psitive crssmatch demnstrated by high panel reactive antibdy (PRA) screen, when a suitable nnreactive live r cadaveric dnr is unavailable in ANY ONE f the fllwing: Kidney Heart (infant) Liver Acute allgraft cardiac rejectin Fcal segmental glmerulsclersis nly when fllwing renal transplant Renal Anti-glmerular basement membrane antibdies (i.e., Gdpasture's syndrme) with prgressive renal failure Antineutrphil cytplasmic antibdy (ANCA) assciated vasculitis (e.g., Wegner s granulmatsis) with assciated renal failure (serum CR abve 5.8 mg/dl) Dense depsit disease with Factr H deficiency and/r elevated C3 Nephritic factr Neurlgic Acute fulminant central nervus system demyelinatin (e.g., Acute Multiple Sclersis, Acute Transverse Myelitis) Severe Guillain-Barré syndrme with ANY ONE f the fllwing: Inability t walk 5 meters withut assistance Cnfinement t bed / chair-bund Ventilatin assistance fr at least part f the day r night This dcument has been classified as public infrmatin
4 Plicy Medical Plicy Manual Draft Revised Plicy: D Nt Implement Acute neurmyelitis ptica (NMO) with ALL f the fllwing met: Failed high-dse intravenus crticsterids Chrnic neurmyelitis ptica (NMO) with ALL f the fllwing met: Failed high-dse crticsterids Failed r nt medically apprpriate azathiprine with r withut lw-dse intravenus crticsterids Failed r nt medically apprpriate mycphenlate mfetil with r withut lw-dse intravenus crticsterids Failed r nt medically apprpriate rituximab Myasthenia gravis in crisis r as part f a preperative preparatin Chrnic inflammatry demyelinating plyneurpathy (CIDP) with ALL f the fllwing: Severe r life-threatening symptms Failed respnse t cnventinal therapy with prednisne r intravenus immunglbulins (IVIg) Meet the cnfirmatry criteria fr CIDP develped by the American Academy f Neurlgy AIDS Task Frce which includes ALL f the fllwing: Nerve bipsy shwing unequivcal evidence f demyelinatin and remyelinatin f prximal nerve segments in which the predminant prcess is demyelinatin Demyelinatin by either electrn micrscpy (greater than 5 fibers) r teased fiber studies (greater than 12% f 50 teased fibers, minimum f fur interndes each, demnstrating demyelinatin/remyelinatin) CSF study - cell cunt less than 10/mm3 if HIV-sernegative r less than 50/mm3 if HIV serpsitive CSF study - negative VDRL Prgressive r relapsing mtr and sensry, rarely n mtr r sensry, dysfunctin f mre than ne limb r a peripheral nerve nature, develping ver at least 2 mnths Nerve cnductin studies including studies f prximal nerve segments in which the predminant prcess is demyelinatin Nerve cnductin studies with 3 r mre f the fllwing: Reductin in cnductin velcity (CV) in tw r mre mtr nerves with ANY ONE f the fllwing: Less than 80% f lwer limit f nrmal (LLN) if amplitude greater than 80% f LLN Less than 70% f LLN if amplitude less than 80% f LLN Partial cnductin blck r abnrmal tempral dispersin in ne r mre mtr nerves: either perneal nerve between ankle and belw fibular head, median nerve between wrist and elbw, r ulnar nerve between wrist and belw elbw with ANY ONE f the fllwing: Criteria suggestive f partial cnductin blck: less than 15% change in duratin between prximal and distal sites and greater than 20% drp in negative peak (-p) area r peak t peak (p-p) amplitude between prximal and distal sites Criteria fr abnrmal tempral dispersin and pssible cnductin blck: greater than 15% change in duratin between prximal and distal sites and greater than 20% drp in -p area r p-p amplitude between prximal and distal sites and greater than 20% drp in -p r p-p amplitude between prximal and distal sites. These criteria are nly suggestive f partial cnductin blck as they are derived frm studies f nrmal individuals. Additinal studies, such as stimulatin acrss shrt segments r recrding f individual mtr unit ptentials, are required fr cnfirmatin. Prlnged distal latencies in tw r mre nerves with ANY ONE f the fllwing: This dcument has been classified as public infrmatin
5 Plicy Medical Plicy Manual Draft Revised Plicy: D Nt Implement Greater than 125% f upper limit f nrmal (ULN) if amplitude greater than 80% f LLN Greater than 150% f ULN if amplitude less than 80% f LLN Absent F-waves r prlnged minimum F-wave latencies (10 t 15 trials) in tw r mre mtr nerves with ANY ONE f the fllwing: Greater than 120% f ULN if amplitude greater than 80% f LLN Greater than 150% f ULN if amplitude less than 80% f LLN IMPORTANT REMINDERS Any specific prducts referenced in this plicy are just examples and are intended fr illustrative purpses nly. It is nt intended t be a recmmendatin f ne prduct ver anther, and is nt intended t represent a cmplete listing f all prducts available. These examples are cntained in the parenthetical e.g. statement. We develp Medical Plicies t prvide guidance t Members and Prviders. This Medical Plicy relates nly t the services r supplies described in it. The existence f a Medical Plicy is nt an authrizatin, certificatin, explanatin f benefits, r a cntract fr the service (r supply) that is referenced in the Medical Plicy. Fr a determinatin f the benefits that a Member is entitled t receive under his r her health plan, the Member's health plan must be reviewed. If there is a cnflict between the Medical Plicy and a health plan, the express terms f the health plan will gvern. ADDITIONAL INFORMATION Based n data frm published studies and/r clinical supprt, plasma exchange is cnsidered medically necessary fr selected cnditins. Fr all ther cnditins, there is a lack f data regarding efficacy and clinical supprt. SOURCES American Academy f Neurlgy. (2016). Cntinuum. Multiple sclersis and ther demyelinating diseases. Retrieved June 30, 2016 frm American Sciety fr Apheresis (2016) Guidelines n the use f therapeutic apheresis in clinical practice evidence-based apprach frm the writing cmmittee f the american sciety fr apheresis: the seventh special issue. Jurnal f Clinical Apheresis, 31, Bambauer, R., Latza, R., Bambauer, C., Burgard, D., and Schiel, R. (2013, Nvember) Therapeutic apheresis in autimmune diseases. Rheumatlgy: Research and Reviews, 5, (Level 2 evidence) Bnnan, M., & Cabre, P. (2012). Plasma exchange in severe attacks f neurmyelitis ptica. Multiple Sclersis Internatinal, 2012, Article ID (Level 1 evidence) Centers fr Medicare & Medicaid Services. CMS.gv. NCD fr apheresis (110.14). Retrieved January 8, 2016 frm Cdrn, P., Cusin, M., Subra, J., Pautt, V., Leturnel, F., Verny, C., et. al., (2017, March) Therapeutic plasma exchange in chrnic dysimmune peripheral neurpathies: A 10-year retrspective study. Jurnal f Clinical Apheresis, [e-published ahead f print] Abstract retrieved July 18, 2017 frm PubMed database. Deschamps, R., Gueguen, A., Parquet, N., Saheb, S., Driss, F., Mesnil, M., et. al. (2016, May) Plasma exchange respnse in 34 patients with severe ptic neuritis. Jurnal f Neurlgy, 263 (5) Abstract retrieved July 18, 2017 frm PubMed database. This dcument has been classified as public infrmatin
6 Plicy Medical Plicy Manual Draft Revised Plicy: D Nt Implement Grsn, L. (2012) An update n the management f chrnic inflammatry demyelinating plyneurpathy. Therapeutic Advances in Neurlgical Disrders, 5 (6), (Level 5 evidence) Kbayashim, M., Nanri, K., Taguchi, T., Ishik, T., Yshida, M., Yshikawa, N. et. al., (2015, February) Immunadsrptin therapy fr neurmyelitis ptica spectrum disrders lng after the acute phase. Jurnal f Apheresis, 30 (1), Abstract retrieved July 18, 2017 frm PubMed database. Mehndiratta, M,, Hughes, R., and Pritchard. J. (2015) Plasma exchange fr chrnic inflammatry demyelinating plyradiculneurpathy. Cchrane Database f Systematic Reviews, Issue 8. Art. N.: CD (Level 2 evidence) Natinal Cmprehensive Cancer Netwrk. (2017, January). NCCN clinical practice guidelines in nclgy. Waldenstrm s macrglbulinemia/lymphplasmacytic lymphma - V Retrieved April 27, 2017 frm Natinal Cmprehensive Cancer Netwrk. (2018, February). NCCN clinical practice guidelines in nclgy (NCCN Guidelines ). Multiple myelma - V Retrieved July 20, 2018 frm Nickersn, M and Marrie, R. (2013) The multiple sclersis relapse experience: patient-reprted utcmes frm the Nrth American Research Cmmittee n Multiple Sclersis (NARCOMS) Registry. BMC Neurlgy, 13 (119). (Level 4 evidence) Oaklander, A., Lunn, M., Hughes, R., van Schaik, I., Frst, C., Chalk, C., et. al (2017, January) Treatments fr chrnic inflammatry demyelinating plyradiculneurpathy (CIDP): an verview f systematic reviews. Cchrane Database Systems Review. January, 13; 1:CD Abstract retrieved April 27, 2017 frm PubMed database. Sherman, E. and Han, M. (2015) Acute and chrnic management f neurmyelitis ptica spectrum disrder. Current Treatment Optins in Neurlgy, 17 (48). (Level 2 evidence) U. S. Fd and Drug Administratin. (2004, July). Center fr Devices and Radilgical Health. 510(k) Pre-market Ntificatin Database. K (Apheresis System). Retrieved Nvember 15, 2010 frm Walsh, M., Catapan, F., Szpirt, W., Thrlund, K., Bruchfeld, A., Guillevin, L. (2011). Plasma exchange fr renal vasculitis and idipathic rapidly prgressive glmerulnephritis: a meta-analysis. American Jurnal f Kidney Disease, 57 (4), (Level 1 evidence - Independent) EFFECTIVE DATE ID_BT This dcument has been classified as public infrmatin
Request for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax
Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus
More informationWidening of funding restrictions for rituximab and eltrombopag
20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More informationFolotyn (pralatrexate)
Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 6/18 Pharmacy- Frmulary 2 x Date f Origin: 11/07 Immune Glbulins Intravenus: Carimune NF, Flebgamma,
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationPolicy. Medical Policy Manual Approved: Do Not Implement Until 1/1/18. Applied Behavioral Analysis (ABA)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/1/18 Applied Behaviral Analysis (ABA) This medical plicy will apply t self-funded grups upn their renewal, beginning 1/1/18. Des nt apply t BlueCare.
More informationITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.
Acute Immune Thrmbcytpenia Purpura (ITP) Backgrund Primary immune thrmbcytpenia (ITP) is an acquired immune mediated disrder characterised by islated thrmbcytpenia, defined as a peripheral bld platelet
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationWound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018
Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered
More informationIMMUNE GLOBULIN (IVIG AND SCIG)
Oxfrd IMMUNE GLOBULIN (IVIG AND SCIG) UnitedHealthcare Oxfrd Clinical Plicy Plicy Number: PHARMACY 033.48 T2 Effective Date: April 1, 2019 Instructins fr Use Table f Cntents Page CONDITIONS OF COVERAGE...
More informationMedical Policy Title: HDC & Autologous ARBenefits Approval: 02/08/2012
Medical Plicy Title: HDC & Autlgus ARBenefits Apprval: 02/08/2012 Stem&/r Prgenitr Cell Supprt, Germ Cell Tumrs Effective Date: 01/01/2013 Dcument: ARB0416:01 Revisin Date: 10/24/2012 Cde(s): 38230, Bne
More informationChronic Fatigue Syndrome
Chrnic Fatigue Syndrme (Als knwn as Myalgic encephalmyelitis/encephalmyelpathy) What is CFS/ME? CFS/ME cmprises a range f symptms that include fatigue, malaise, headaches, sleep disturbances, difficulties
More informationLyme Disease Surveillance in North Carolina
Lyme Disease Surveillance in Nrth Carlina 2008-2014 Carl Williams DVM Megan Sanza MPH Cmmunicable Disease Branch Divisin f Nrth Carlina Public Health Lyme Disease Surveillance in Nrth Carlina 2008-2014
More informationPaediatric Sepsis Form. Sinéad Horgan SSWHG Sepsis Lead
Paediatric Sepsis Frm Sinéad Hrgan SSWHG Sepsis Lead www.hse.ie/sepsis Definitin A life-threatening rgan dysfunctin due t a dysregulated hst respnse t infectin N cnfirmatry test Bld cultures are psitive
More informationMy Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)
My Symptms and Medical Histry fr Adult Chrnic Immune Thrmbcytpenia (ITP) Call t talk t a registered nurse 1-855-7Nplate (1-855-767-5283), Mnday Friday, 9:00 AM 9:00 PM ET Indicatin Nplate is a man-made
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationIMMUNE GLOBULIN (IVIG AND SCIG)
IMMUNE GLOBULIN (IVIG AND SCIG) UnitedHealthcare Oxfrd Clinical Plicy Plicy Number: PHARMACY 033.43 T2 Effective Date: February 1, 2018 Table f Cntents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationYear 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:
Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:
More informationYescarta (axicabtagene ciloleucel) (Intravenous)
Yescarta (axicabtagene cilleucel) (Intravenus) Last Review Date: 10/31/2017 Date f Origin: 10/31/2017 Dates Reviewed: 10/2017 Dcument Number: IC-0333 I. Length f Authrizatin Cverage will be prvided fr
More informationMeeting the Nutritional Requirements of Individuals with Dementia
Unit 15: Understanding and Meeting the Nutritinal Requirements f Individuals with Dementia Unit reference number: D/616/7124 Level: 3 Unit type: Optinal Credit value: 3 Guided learning hurs: 26 Unit summary
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationErythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals
(Subcutaneus/Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.80 *NON-DIALYSIS* Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationDrug Therapy Guidelines
Applicable* Medical Benefit x Effective: 2/15/19 Pharmacy- Frmulary 1 Next Review: 12/19 Pharmacy- Frmulary 2 Date f Origin: 4/1/05 Pharmacy- Frmulary 3/Exclusive Review Dates: 4/1/05, 2/1/06, 10/15/06,
More informationConsensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline
Practice Guideline: Clinical Guide Cnsensus Recmmendatins fr the Management f Chrnic Lymphcytic Leukemia: Primary Care Guideline CCMB Practice Guideline Clinical Guide Develped by: Lymphprliferative Disrders
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationImproving Surveillance and Monitoring of Self-harm in Irish Prisons
HSE Mental Health Divisin Stewart s Hspital, Palmerstwn, Dublin 20 Tel: 01 6201670 Email: inf@nsp.ie www.nsp.ie Imprving Surveillance and Mnitring f Self-harm in Irish Prisns Prject Scpe Dcument 8 th June
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationMEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache
MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management
More informationBRCA1, BRCA2 and PALB2 Testing for Breast, Ovarian and Other Cancers
Plicy Medical Plicy Manual Draft Revised Plicy: D Nt Implement BRCA1, BRCA2 and PALB2 Testing fr Breast, Ovarian and Other Cancers DESCRIPTION Hereditary breast and varian cancer (HBOC) syndrme describes
More informationPROVIDER ALERT. Comprehensive Diagnostic Evaluation (CDE) Guidelines to Access the Applied Behavior Analysis (ABA) Benefit.
Cmprehensive Diagnstic Evaluatin (CDE) Guidelines t Access the Applied Behavir Analysis (ABA) Benefit May 5, 2017 Clinical infrmatin that utlines medical necessity is required t supprt the need fr initial
More informationRituxan (rituximab) Document Number: IC-0109
Rituxan (rituximab) Dcument Number: IC-0109 Last Review Date: 10/31/2017 Date f Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012,
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationΥποτροπιάζουσες Περικαρδίτιδες: Τι νεότερο; Γεώργιος Λάζαρος Επιμελητής Α Α Πανεπιστημιακή Καρδιολογική Κλινική Ιπποκράτειο Γ.Ν.
Υποτροπιάζουσες Περικαρδίτιδες: Τι νεότερο; Γεώργιος Λάζαρος Επιμελητής Α Α Πανεπιστημιακή Καρδιολογική Κλινική Ιπποκράτειο Γ.Ν. Αθηνών Recurrent pericarditis after an initial episde f pericarditis ranges
More informationName: Date: Period: Notes: The Blood and Lymphatic System
Name: Date: Perid: Cmpsitin f Bld and their Functins Red Bld Cells (aka ) Structure Ntes: The Bld and Lymphatic System D nt have a like ther cells d Cntain a specialized prtein called Hemglbin cntains
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationYou may have a higher risk of bleeding if you take warfarin sodium tablets and:
MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain
More informationUpdates to Medical Policies and Clinical UM Guidelines
Updates t Medical Plicies and Clinical UM Guidelines Effective May 1, 2016 The majr new plicies and changes are summarized belw. Please refer t the specific plicy fr cding, language, and ratinale updates
More informationOriginal Policy Date 12:2013
MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our
More informationHIP REPLACEMENT SURGERY (ARTHROPLASTY)
Prtcl: ORT015 Effective Date: June 1, 2017 HIP REPLACEMENT SURGERY (ARTHROPLASTY) Table f Cntents Page COMMERCIAL & MEDICAID COVERAGE RATIONALE... 1 MEDICARE COVERAGE RATIONALE... 3 U.S.FOOD AND DRUG ADMINISTRATION
More informationGuideline Number: NIA_CG_301 Last Revised Date: October 2014 Responsible Department: Implementation Date: October 2014 Clinical Operations
Natinal Imaging Assciates, Inc. Clinical guidelines PARAVERTEBRAL FACET JOINT INJECTIONS OR BLOCKS CPT Cdes: Cervical Thracic Regin: 64490 (+ 64491, +64492), 0213T (+0214T, +0215T) Lumbar Sacral Regin:
More informationOntario s Referral and Listing Criteria for Adult Lung Transplantation
Ontari s Referral and Listing Criteria fr Adult Lung Transplantatin Versin 2.0 Trillium Gift f Life Netwrk Adult Lung Transplantatin Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The patient referral
More informationPolicy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning
Plicy Guidelines: Genetic Testing fr Carrier Screening and Reprductive Planning Cntents Overview... 1 Cverage guidelines... 2 General cverage guidelines... 2 Rutine carrier screening... 2 Carrier screening
More informationHigh Performance Network Quality Criteria for Designation
Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationSpecifically, on page 12 of the current evicore draft, we find the statement:
Octber 23, 2016 evicre Healthcare Attn: Dr Greg Allen 400 Buckwalter Place Bulevard Blufftn, SC 29910 RE: evicre Draft Onclgy Imaging Guidelines, v 19.0 Gentlepersns: Prstate Cancer Internatinal is a nt-fr-prfit
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationBedfordshire and Hertfordshire DRAFT Priorities forum statement Number: Subject: Prostatism Date of decision: January 2010 Date of review:
Bedfrdshire and Hertfrdshire DRAFT Pririties frum statement Number: Subject: Prstatism Date f decisin: January 2010 Date f review: Referral criteria Mst men with lwer urinary tract symptms due t benign
More informationICD-10-CM Coding Basics Chapter Specifics
ICD-10-CM Cding Basics Chapter Specifics Chapter 15 Pregnancy, Childbirth and the Puerperium Vilma Smith, LVN, CPC, CCS Debra Bales, LVN, CPC Jnay Rischer, CPC 1 Rev. May 2015 ICD-10-CM Cnventins General
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More informationPage 1 of 5. Fast Facts. CTC v.4; AJCC 7 th ed. Herceptin provided
Page 1 f 5 NSABP B-47 - A Randmized Phase III Trial f Adjuvant Therapy Cmparing Chemtherapy Alne (Six Cycles f Dcetaxel Plus Cyclphsphamide r Fur Cycles f Dxrubicin Plus Cyclphsphamide Fllwed by Weekly
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationProtocol. Genetic Testing for Human Leukocyte Genes (HLA)
Prtcl Genetic Testing fr Human Leukcyte Genes (HLA) Medical Benefit Effective Date: 01/01/17 Next Review Date: 11/18 Preauthrizatin Yes Review Dates: 11/16, 11/17 Preauthrizatin is required fr ankylsing
More informationALCAT FREQUENTLY ASKED QUESTIONS
1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age
More informationBANKMED MEDICAL SCHEME. MEDICINE ADVISORY SERVICES (Chronic Medicine Benefit) GENERAL INFORMATION
BANKMED MEDICAL SCHEME MEDICINE ADVISORY SERVICES (Chrnic Medicine Benefit) GENERAL INFORMATION LIST OF CHRONIC CONDITIONS Cnditins cvered under Bankmed s chrnic medicatin benefit are detailed belw. REGISTRATION
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationGeneric Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations
Dear Clleague Generic Immunsuppressants in the Specialist Area f Transplantatin Cnsensus n Implicatins and Practical Recmmendatins Executive Summary Slid-rgan transplants are the best pssible treatment
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationSignificance of Chronic Kidney Disease in 2015
1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationPain relief after surgery
Pain relief after surgery Imprtant infrmatin fr patients www.mchft.nhs.uk We care because yu matter This leaflet is designed t help yu cntrl any pain yu may have at hme fllwing yur peratin. Please read
More informationClinical Policy: Immune Globulins Reference Number: ERX.SPA.134 Effective Date:
Clinical Plicy: Reference Number: ERX.SPA.134 Effective Date: 03.01.14 Last Review Date: 08.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal infrmatin. Descriptin
More informationVaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE
Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationCDC Influenza Division Key Points November 7, 2014
In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationWCPT awards programme 2015
WCPT awards prgramme 2015 The WCPT awards prgramme recgnises utstanding cntributins and leadership by individual physical therapists and grups t the prfessin and/r glbal health at an internatinal level.
More informationRituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY
Rituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY 1. Backgrund and indicatins Rituximab is a mnclnal antibdy that wrks by remving B-cells (a type f white bld cell that prduce antibdies). The aim f the B cell
More informationSCIG: Hizentra, Gammagard Liquid, Gamunex -C, Gammaked, Hyqvia, Cuvitru (immune globulin SQ)
SCIG: Hizentra, Gammagard Liquid, Gamunex -C, Gammaked, Hyqvia, Cuvitru (immune glbulin SQ) Dcument Number: IC-0059 Last Review Date: 04/03/2018 Date f Origin: 7/20/2010 Dates Reviewed: 9/2010, 12/2010,
More informationDRAFT Policy for the Management of Ear Wax
Clinical Cmmissining Grup (CCG) Treatment Plicy NHS Birmingham and Slihull Clinical Cmmissining Grup NHS Sandwell and West Birmingham Clinical Cmmissining Grup DRAFT Plicy fr the Management f Ear Wax 1
More informationDonor Lymphocyte Infusion for Malignancies Treated with an AllogeneicHematopoietic Stem-Cell Transplant
Medical Plicy 2.03.03 Dnr Lymphcyte Infusin fr Malignancies Treated with an AllgeneicHematpietic Stem-Cell Transplant Sectin 2.0 Medicine Subsectin 2.03 Onclgy Effective Date September 30, 2014 Original
More informationImmune Globulins (immunoglobulin) (Intravenous)
Immune Glbulins (immunglbulin) (Intravenus) Last Review Date: 09/05/2018 Date f Origin: 07/20/2010 Dcument Number: MODA-0071 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 06/2011, 09/2011, 10/2011,
More informationReference: Patient A. Brenda WXXXXX Date of Birth: 4/15/57
Reference: Patient A Brenda WXXXXX Date f Birth: 4/15/57 49 year ld white female patient presented n July 20, 2006 with chief cmplaint f stage 4 cancer, initially diagnsed in Octber, 2003 with Cervical
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationMEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion
MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new
More information2017 CMS Web Interface
CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...
More informationXX Abraxane 100 MG SUSR (CELGENE CORP)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP) DESCRIPTION Paclitaxel is a natural prduct with antitumr
More informationPromoting Nutrition and Hydration in Care Settings
Unit 43: Prmting Nutritin and Hydratin in Care Settings Unit reference number: F/616/7360 Level: 3 Unit type: Optinal Credit value: 4 Guided learning hurs: 32 Unit summary What individuals eat and drink
More informationVaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE
Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationMedical Policy Manual Approved Revised Policy: Do Not Implement Until 4/30/19
Medical Manual Apprved Revised : D Nt Implement Until 4/30/19 Aqueus Shunts and Stents fr Glaucma DESCRIPTION Aqueus shunts and stents fr the treatment f glaucma create an alternative path fr aqueus humr
More informationAccess to Heme Treatment in Canada - Survey 2018
Access t Heme Treatment in Canada - Survey 2018 The Canadian Assciatin fr Prphyria/Assciatin Canadienne de Prphyrie (CAP/ACP) asserts that patients with acute prphyria shuld have access t Hemin treatment,
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationReliability and Validity Plan 2017
Reliability and Validity Plan 2017 Frm CAEP The principles fr measures used in the CAEP accreditatin prcess include: (a) validity and reliability, (b) relevance, (c) verifiability, (d) representativeness,
More informationSummary of Significant Changes. Policy
This Plicy replaces POL229/3 Cpy Number Effective 17/05/17 Summary f Significant Changes Updated survival rates fllwing heart transplantatin. Edited Sectin 6.2 in light f new prcess fr urgent heart-lung
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationo Procedures performed o Diagnoses Identified o Certain devices/equipment/supplies acquired for patient
Image Surce: https://s-media-cache-ak0.pinimg.cm/736x/7c/29/91/7c2991805f004e1ca05e42a79883f4a7.jpg 6/30/2017 Curse Objectives A Practical Guide t Cding fr Audilgists in 2017 Megan Keirans, AuD University
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More information